Supercharge Your Innovation With Domain-Expert AI Agents!

Novel peptides, compositions comprising the same and uses thereof in methods for the treatment of metabolic, cardiac and immune-related disorders

A technology for immune-related diseases and compositions, applied in the field of novel peptides, can solve problems such as insulin that has not progressed

Inactive Publication Date: 2014-06-11
两合生物科技公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in pre-IDDM the disruption, if present, has not progressed sufficiently to require administration of insulin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel peptides, compositions comprising the same and uses thereof in methods for the treatment of metabolic, cardiac and immune-related disorders
  • Novel peptides, compositions comprising the same and uses thereof in methods for the treatment of metabolic, cardiac and immune-related disorders
  • Novel peptides, compositions comprising the same and uses thereof in methods for the treatment of metabolic, cardiac and immune-related disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0254] Isolation of APC-2 cDNA

[0255] Have the cDNA of the sequence shown in SEQ ID NO.2, its coding peptide APC-2 (have the sequence shown in SEQ ID NO.1), use the human cDNA library purchased from Clonetech and here as SEQ ID NO. The primers shown in 3 and 4 amplify it.

[0256]Regarding the APC-2 peptide, which is also named Uzi-1 herein, a maximum cleavage site likelihood of p=0.760 was determined between amino acid positions 17 and 18.

[0257] The PCR products were sequenced. PCR products were analyzed on agarose gels and stained using Cyber ​​Green (Invitrogene), and the intensity of PCR products was assessed using a BioRad ChemiDoc analyzer. The results show that APC-2 is expressed in human heart and lymphocytes.

Embodiment 2

[0259] APC-2 improves glucose tolerance

[0260] Male C57Bl / 6 mice were divided into 4 groups of 5 mice each. The control group (Group I) received 5% mannitol IV (3 times a week, 200 μL each time). Group II received doses of APC2 (0.25 mg / Kg body weight) 3 times a week. Group III received doses of APC2 (1.5 mg / Kg body weight) 3 times a week. Group IV received doses of APC2 (15 mg / Kg body weight) 3 times a week. Mice were treated for 2 weeks.

[0261] At the end of the experiment, a glucose tolerance test (GTT) was administered as described in the methods section. exist figure 1 The results of GTT are shown in . It can be clearly seen that APC-2 improves glucose tolerance in a dose-dependent manner, with an optimal response observed for an APC2 dose of 1.5 mg / Kg body weight.

Embodiment 3

[0263] APC-2 reduces plasma glucagon

[0264] Mouse plasma glucagon levels were analyzed as described in the Methods section, except for the GTT. Such as figure 2 As shown, plasma glucagon levels were reduced in a dose-dependent manner by APC-2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to polypeptides exhibiting metabolic-modulating as well as immunomodulatory properties, nucleic acids encoding them, compositions comprising them, and methods of treating metabolic disorders and / or immune-related disorders comprising their administration and to their use in preparing pharmaceutical compositions for the treatment, amelioration, prophylaxis or delaying the onset of at least one of a metabolic disorder and an immune-related disorder.

Description

technical field [0001] The present invention relates to novel peptides exhibiting metabolic modulating as well as immunomodulatory properties. More specifically, the present invention provides novel peptides capable of improving metabolic parameters associated with diabetes and its pathogenesis, as well as other metabolic disorders such as metabolic syndrome, but also immune-related diseases and heart diseases. The invention is also directed to compositions containing said peptides, methods of treatment comprising their administration and their use in the manufacture of said compositions. Background technique [0002] The discussion in this section is not limited to subject matter that qualifies as "prior art" for this invention. Accordingly, no admission is made that such state of the art should be implied or inferred by virtue of incorporation of particular subject matter in this discussion, nor is it stated that an objection to the inventors' purposes should be implied b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/435C12N15/12A61K38/17A61P3/00
CPCA61K38/00C07K14/4702C07K14/575C07K14/47A61P25/00A61P3/00A61P37/02A61P3/10
Inventor T·山德勒O·德伟瑞
Owner 两合生物科技公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com